Particle Size Uniformity in Nanocosmetic Manufacturing: What a Multi-Angle DLS Signature Verifies

Why polydispersity index (PDI) is a meaningful, and often misapplied, quality signal for nano-scale cosmetic delivery systems - and why NanoBase™ verifies particle size distribution architecture-wide rather than against a single PDI threshold.

DOI Reference: 10.5281/zenodo.18616576

What Particle Size Distribution Measures at the Nano-Scale

Polydispersity index quantifies the breadth of particle size distribution in a colloidal system. Derived from cumulant analysis of Dynamic Light Scattering (DLS) autocorrelation data, PDI ranges from 0 (a single uniform population) to 1.0 (highly heterogeneous). For a single-carrier system, PDI is a straightforward read on quality: a tight, uniform population behaves predictably, while a broad one signals aggregation, degradation, or process drift.

NanoBase™ tri-domain formulations are different by design. They integrate nanoemulsion, nanoliposomal, and nanomicellar carrier populations in a single continuous phase - three engineered domains, each sized for a different payload class, coexisting on purpose. Measured as one bulk PDI value, that intentional multi-population structure reads as broader dispersity than a single-carrier system would, even when every domain is behaving exactly as engineered. That is why NanoBase™ is not released against one dispersity number: each batch is characterised by multi-angle DLS and released against its own engineered distribution signature, which resolves the three domains individually rather than averaging them into one figure that would misrepresent the architecture.

Single-Carrier Standards vs. a Multi-Domain Architecture

Pharmaceutical nanoparticle formulations typically target PDI below 0.30, with sub-0.20 values preferred for single-carrier injected therapeutics, where one uniform population is the goal. Cosmetics carry no equivalent regulatory threshold, which is part of why “nano” gets used loosely across the industry without population uniformity ever being verified.

That standard makes sense for a single-carrier system claiming one uniform particle population. It does not transfer cleanly to an architecture that is engineered to be trimodal. Applying a single-population PDI ceiling to a three-domain system would either be meaningless, if it passes without telling you whether any individual domain is well-controlled, or actively misleading, if it is used to imply a monodispersity that was never the design goal. NanoBase™’s approximately 185 nm mean particle diameter is the published design target; per-domain distribution is what is actually verified at QC, batch to batch.

How Particle Size Determines Deposition Pathway

Each NanoBase™ domain is assigned a payload class by design: the nanoemulsion domain carries lipophilic actives, the nanoliposomal domain organises amphiphilic and peptide payloads, and the nanomicellar domain solubilises hydrophilic molecules. A domain with poor internal uniformity, regardless of what a single bulk PDI number reads, means some fraction of that payload class is not riding in the carrier population it was assigned to. That is the gap a multi-angle DLS signature is built to catch, and a single bulk figure cannot.

Manufacturing Controls for Distribution Control

Maintaining tight per-domain distribution requires process engineering beyond standard homogenisation: sequential domain assembly, energy input calibrated to each carrier type’s critical properties, and real-time DLS monitoring during scale-up.

Traditional manufacturing monitors viscosity and centrifugal stability, metrics that are largely insensitive to nanoscale distribution changes. A macroemulsion can hold “stable” viscosity while its sub-micron fraction is changing underneath it. DLS monitoring is what actually catches that, which is why NanoBase™ runs a DLS characterisation on every batch.

Distribution Trending as a Shelf-Stability Signal

A rising distribution-width trend across accelerated-aging timepoints is often the earliest detectable sign of instability, visible in the DLS data well before turbidity, viscosity, or pH shift enough to notice by eye or bench measurement. That is the general principle behind why nano-delivery formulators track DLS across stability studies rather than relying on classical macro-scale indicators alone.

Implications for Brand Partners and Formulators

Brands evaluating a nano-delivery platform should ask for two things: the mean particle diameter, and the DLS methodology used to verify it, specifically whether it is multi-angle or single-angle, and whether it is run per batch or only at initial characterisation. Those two points are the minimum needed to tell genuine nano-scale, batch-verified delivery apart from a marketing claim with no analytical backing behind it.